Key result
Opioid-related symptom distress scale (SDS) scores and clinically meaningful events were strongly associated with specific validation measures from a postoperative recovery survey.
Why the study?
Is the Perioperative Opioid-Related Symptom Distress Scale a valid tool for assessing opioid-related symptoms in patients undergoing laparoscopic cholecystectomy?
RCT (n=193)
placebo-controlled
randomized
Is the Perioperative Opioid-Related Symptom Distress Scale a valid tool for assessing opioid-related symptoms in patients undergoing laparoscopic cholecystectomy?
Answers are grounded in this paper and cite their sources.
The Perioperative Opioid-Related Symptom Distress Scale is a valid and reliable tool for assessing postoperative opioid-related symptoms.
In Brief A reduction in opioid use may reduce the incidence and severity of opioid-related side effects. However, no published studies have demonstrated this relationship. In a prospective, placebo-controlled, randomized trial of analgesia for laparoscopic cholecystectomy, we validated an opioid-related symptom distress scale (SDS) questionnaire and clinically meaningful events (CMEs). A total of 193 patients completed the SDS questionnaire every 24 h after discharge for 7 days. This analysis was based on data from Day 1 only. The SDS assessed 12 common opioid-related symptoms, including nausea, vomiting, and difficulty passing urine, by 3 ordinal measures: frequency, severity, and bothersomeness. Patients with responses of “frequently” to “almost constantly,” “moderate” to “very severe,” or “quite a bit” to “very much bothered” were considered to have a CME. A detailed postoperative recovery survey of patient functional status and experience ofadverseeffectswasusedtovalidatetheSDS.Validation measures in the recovery survey were categorized as non-specific (e.g., level of normal activities) and specific (e.g., number of times vomited in 24 h, minutes of nausea in 24 h, and ability to void normally). SDS scores and CMEs for nausea, vomiting, and difficulty passing urine were strongly associated with three related validation measures from the recovery survey: minutes of nausea within 24 h, number of times vomited within 24 h, and ability to void normally, respectively (P < 0.0001). There was also a strong association between SDS scores and CMEs for nausea, vomiting, and voiding and general recovery validation measures, although the association was significantly weaker than that for symptom-specific validation measures. CMEs for nausea, vomiting, and voiding showed a high specificity and lower sensitivity with directly assessed responses. The SDS questionnaire and CMEs are valid tools for assessing postoperative opioid-related symptoms after laparoscopic cholecystectomy. Symptoms defined as CMEs through the SDS may be more sensitive than those identified by direct assessment. IMPLICATIONS: The symptom distress scale (SDS) was designed to evaluate the level of distress associated with the adverse effects of commonly used opiates. This study reports on the reliability and validity of the SDS in a group of patients undergoing laparoscopic cholecystectomy. The validity of the SDS was demonstrated by using specific symptoms directly assessed in the clinical trial and patient responses to questions regarding general satisfaction and daily activities.
No takes yet. Share an insight, caveat, or question.
Apfelbaum et al. (2004) conducted an RCT in laparoscopic cholecystectomy (n=193). Analgesia vs. Placebo was evaluated on Association of SDS scores and clinically meaningful events with related validation measures from the recovery survey (p=<0.0001). Opioid-related symptom distress scale (SDS) scores and clinically meaningful events were strongly associated with specific validation measures from a postoperative recovery survey.
Synapse has enriched 10 related papers. Consider them for comparative context: